ADMA - ADMA Biologics expects first-time positive EBITDA by second half of year
2023-03-23 17:33:55 ET
- ADMA Biologics ( NASDAQ: ADMA ) said it is expecting to generate positive EBITDA by the second half of 2023.
- The company also said it projects 2023 revenues to surpass $210M. Consensus is $211.04M.
- In 2024, ADMA ( ADMA ) is estimating top-line revenue of at least $250M, and at least $300M after that.
- The company is also projecting net income of $50M-$100M in 2024-25 "and beyond."
- In Q4 2022, ADMA ( ADMA ) beat on the top and bottom lines .
- In the quarter, the company saw its net loss narrow ~27% to $12.2M (-$0.06 per share basic and diluted vs. -$0.09).
- ADMA ( ADMA ) ended the year with cash and cash equivalents of ~$86.5M, a 69% increase compared to the end of 2021.
- Read why Seeking Alpha contributor Zach Bristow considers ADMA ( ADMA ) a buy.
For further details see:
ADMA Biologics expects first-time positive EBITDA by second half of year